Genzyme plant shutdown spells Protalix opportunity

As a result of the mid-June Genzyme plant shutdown, which brought a halt to the manufacture of enzyme-replacement treatments Cerezyme and Fabrazyme for Gaucher disease and Fabry disease, respectively, the FDA has approached Protalix to start providing its experimental Gaucher's disease therapy prGCD to patients under an expanded access program.

Protalix is discussing a treatment protocol with regulators to expand use of the therapy, a plant-cell expressed recombinant form of glucocerebrosidase now in a late-stage trial, reports sister publication FierceBiotech.

The shutdown of the Boston-area Genzyme plant is the result of a decontamination effort now underway due to Vesivirus 2117 contamination in a bioreactor. The biotech giant faces extended rationing of the two drugs after deciding to sanitize the entire manufacturing facility rather than just the cell-culture production area.

- here's the FierceBiotech report
- see our coverage of the Genzyme plant closure


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.